UBS Group
AERI

UBS Group’s Aerie Pharmaceuticals AERI Stock Holding History

UBS Group’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-100,000
Closed -$1.35M – 8532
2020
Q1 		$1.35M Buy
+100,000
New +$1.9M ﹤0.01% 3105

UBS Group's AERI Position: Q4 2022 in Review

UBS Group sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 2,405,832 shares — an estimated $36.4M sold.

UBS Group first reported a position in AERI in Q4 2014 and held it in 31 quarters. The position peaked at $36.4M in Q3 2022. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.

  • UBS Group reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • UBS Group sold 2,405,832 Aerie Pharmaceuticals shares in Q4 2022, an estimated $36.4M.
  • UBS Group first reported a position in Aerie Pharmaceuticals in Q4 2014 and held it in 31 quarters.
  • UBS Group's Aerie Pharmaceuticals position peaked at $36.4M in Q3 2022.
  • 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.

Based on UBS Group's 13F filing for Q4 2022, filed 8 Feb 2023.